In conclusion, in these studies we have demonstrated that selected agonists at the IP, β2, EP2, EP4, and A2B receptors have the potential to inhibit pro-fibrotic processes such as fibroblast proliferation and differentiation, implying a potential for disease modifying effects in IPF. Here, PTGER4 is linked to idiopathic pulmonary fibrosis.